AI PRICE FORECAST
MDT Stock Forecast & AI Price Prediction
Medtronic · Healthcare · Medical Devices
MDT live signal snapshot
Shares of MDT were last at $101.61, up 0.02% on the day, trading 4.4% below its 52-week high of $106.33 and 38.6% above its 52-week low of $73.31. Our AI model's current call on MDT is HOLD, with 71% confidence. The technical signals aren't aligned enough for a directional call yet. The short-term averages line up bullishly, and the price is holding above its 50-day line. Its one-month projection is about $100.95, a -0.6% move from the last price.
MDT's 14-day RSI is 65.7 — healthy bullish momentum without being overextended. The MACD indicator sits over its signal line, and the histogram reading of 0.36 shows buying pressure building. Its 50-day average ($93.35) is holding 5.8% above the 200-day ($88.25), the pattern chartists call a golden cross.
26 Wall Street analysts covering MDT put the average price target at $105.00 (range $85.00–$121.00), implying 3.3% upside from the current price. The current recommendation trend leans bullish: 19 Buy/Strong Buy ratings vs 0 Sell/Strong Sell (and 11 Hold).
Live figures from real market data feeds, current as of the last site build. Open the interactive MDT dashboard for numbers updated throughout today's session.
About Medtronic
Medtronic plc (MDT) is a medical devices company in the healthcare sector, headquartered in Galway, Ireland. Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It has a market value of about $130.0 billion and roughly 95,000 full-time employees. With a beta of 0.57, the stock has historically moved less than the overall market.
MDT performance vs. the market
Since the start of 2026 the stock has risen 5.8%, behind the S&P 500 (+11.4%) and behind the healthcare sector fund XLV (+22.1%). Over the past 12 months the stock has gained 9.7%, roughly in line with the S&P 500. Its +9.2% move over the past month extends a +12.2% three-month run.
| Period | MDT | Sector (XLV) | S&P 500 |
|---|---|---|---|
| 1 month | +9.2% | +11.4% | −2.3% |
| 3 months | +12.2% | +12.2% | −2.3% |
| Year to date | +5.8% | +22.1% | +11.4% |
| 1 year | +9.7% | +28.3% | +11.5% |
Medtronic financials at a glance
Medtronic's most recent quarter (ended Apr 30, 2026) brought in $9.8 billion of revenue and net income of $1.2 billion (a 12.7% net margin). Revenue was up 13.7% from the same quarter a year earlier. The stock trades at a price-to-earnings ratio of 25.0 on trailing earnings of $4.07 per share. Trailing free cash flow was $5.4 billion, and total debt equals 55% of shareholders' equity.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Apr 30, 2026 | $9.8B | $1.2B |
| Jan 31, 2026 | $9.0B | $1.1B |
| Oct 31, 2025 | $9.0B | $1.4B |
| Jul 31, 2025 | $8.5B | $1.0B |
MDT vs. its peers
MDT's +5.8% this year ranks ahead of 4 of the 5 big healthcare names below. The strongest of the group this year is Edwards Lifesciences (EW, +24.1%).
| Company | Price | YTD | P/E | AI verdict |
|---|---|---|---|---|
| Medtronic (MDT) | $101.61 | +5.8% | 25.0 | HOLD |
| Abbott Laboratories (ABT) | $109.29 | −12.8% | 40.8 | HOLD |
| Stryker (SYK) | $318.79 | −9.3% | 33.9 | HOLD |
| Boston Scientific (BSX) | $45.13 | −52.7% | 19.0 | HOLD |
| Edwards Lifesciences (EW) | $105.81 | +24.1% | 61.5 | BUY |
| GE HealthCare Technologies (GEHC) | $82.60 | +0.7% | 17.5 | BUY |
MDT stock: common questions
What is the MDT stock price target?
26 Wall Street analysts put the average 12-month target at $105.00, in a range of $85.00–$121.00, versus a recent price of $101.61. Stock Pulse 247's model projects about $100.95 over the next month.
Is MDT a buy right now?
Our AI model currently rates MDT a HOLD at 71% confidence. Among analysts, 19 rate it Buy or Strong Buy, 11 Hold and 0 Sell. Neither is personal advice — weigh them with your own research and risk tolerance.
How has MDT stock performed this year?
Since the start of 2026 the stock has risen 5.8%, behind the S&P 500 (+11.4%) and behind the healthcare sector fund XLV (+22.1%). Over the past 12 months the stock has gained 9.7%, roughly in line with the S&P 500. Its +9.2% move over the past month extends a +12.2% three-month run.
What is MDT's 52-week high and low?
MDT has traded between $73.31 and $106.33 over the past 52 weeks; at $101.61 it is 4.4% below its 52-week high of $106.33 and 38.6% above its 52-week low of $73.31.
What sector is MDT in, and who are its peers?
MDT is in the healthcare sector (medical devices). Its largest peers on Stock Pulse 247 include Abbott Laboratories (ABT), Stryker (SYK), Boston Scientific (BSX), Edwards Lifesciences (EW).
How accurate is the MDT forecast?
It's a model estimate from price history, technical indicators and analyst targets, not a guarantee — no model predicts short-term moves reliably. Use it as one input alongside your own research.
How this works: the forecast combines MDT's price history, momentum indicators (RSI, MACD, moving averages), volatility and analyst targets into one estimate. It's a model, not a guarantee.